Persephone Biosciences

Persephone Biosciences is on a mission to unlock the potential of the microbiome to prevent and treat disease. We were co-founded in 2017 by synthetic biologists Stephanie Culler, Ph.D. and Steve Van Dien, Ph.D. Research drives everything we do - from decoding the infant microbiome to developing next-generation probiotics and disease-preventing therapeutics. We have four groundbreaking clinical studies ongoing: ARGONAUT (NCT04638751), My Baby Biome (NCT05472688), ARTEMIS (NCT06746285) and AMBROSIA (NCT06091813).

Content by Persephone Biosciences

A health care professional assessing a baby, highlighting the importance of addressing early childhood health.

The Gut Microbiome Protects Infants from Chronic Diseases

By The Scientist and Persephone Biosciences | | 4 min read

Page 1 of 1 - 1 Total Items

September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Explore how emerging biomarker research and ultrasensitive multiplex proteomics are revealing molecular signatures associated with neurodegeneration, inflammation, and disease progression in amyotrophic lateral sclerosis (ALS).

Best Practices for qPCR Assay Design and Optimization

Explore practical strategies for designing, optimizing, and validating qPCR assays to improve specificity, reproducibility, and confidence across routine and high-throughput gene expression studies.

Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

Explore strategies for navigating critical analytical decisions in single-cell RNA sequencing and spatial transcriptomics, from quality control and data integration to clustering, marker selection, and cell-type annotation.

Scientist reviewing cellular and molecular data on a computer in a laboratory.

Building Translation-Ready Biomarkers with Connected Workflows

Identify sources of variability and approaches for improving consistency across biomarker development.